GLP-1 side effects: how common is each one?

The common ones

Almost everything frequent is gastrointestinal, and almost all of it follows directly from delayed gastric emptying. Across the trial programmes the pattern is consistent ^[5][6][8]:

Typical frequency bands from the randomised trials
Effect	Roughly how common	Pattern
Nausea	Very common (a third to a half)	Peaks after each dose step, then settles
Diarrhoea	Common	Often early, usually transient
Constipation	Common	Can persist; often the more annoying long-term complaint
Vomiting	Common	Strongly dose-related
Abdominal pain, reflux, burping	Common	Usually mild
Injection-site reactions	Uncommon	Mild
Stopping because of side effects	A few per cent	Higher at top doses

The gap between "a third of people feel sick" and "a few per cent stop" is the most useful number here. Most people who get nauseated push through it, usually because it improves.

The rare ones people worry about

Pancreatitis, gallbladder disease, thyroid C-cell tumours and gastroparesis dominate the online discussion far out of proportion to their frequency in the data.

Gallbladder disease. Genuinely increased, but this is substantially a consequence of rapid weight loss itself rather than a direct drug toxicity — rapid weight loss by any means raises gallstone risk.
Pancreatitis. Watched intensively across the whole class. Large meta-analyses of cardiovascular and kidney outcome trials have not produced the signal that early case reports implied ^[1].
Thyroid C-cell tumours. The warning derives from rodent studies. It has not translated into a demonstrated human signal, but it is why the drugs are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2.
Gastroparesis. Delayed gastric emptying is the intended mechanism, as covered on the mechanism page. Severe persistent gastroparesis is a different and much rarer thing.

Absence of major safety signals in pooled trial data

What the newer oral agents look like

The oral small-molecule agonists have now been through large randomised trials in both obesity and early type 2 diabetes ^[2][3][4]. Their tolerability profile looks like the injectables — dominated by the same gastrointestinal effects, with the same dose-escalation strategy. Being a pill does not change the mechanism, and therefore does not change the side effects. More on the oral options.

Where trial data and real life diverge

Trial populations are screened, supervised and escalated on protocol. A 2025 review of real-world utilisation and effectiveness found the broad safety picture holds up outside trials, but with more variability — driven by faster escalation, dose interruptions, supply gaps and compounded products of uncertain content ^[9]. Most of the worst outcomes reported outside trials involve non-prescription sourcing rather than the drugs themselves.

Common questions

Does the nausea ever go away completely?

For most people it settles within weeks of a given dose, and returns briefly at each increase. Constipation is the effect most likely to persist.

Is hair loss a side effect?

Hair shedding is a well-known consequence of rapid weight loss in general — telogen effluvium — rather than a specific drug toxicity. It is usually temporary.

Should I stop before surgery?

Ask your anaesthetist. There is specific perioperative guidance because the stomach may not be empty after standard fasting.

Do side effects mean it is working?

No. Nausea and weight loss are both dose-related, but individuals vary widely in both. Plenty of people lose a lot of weight without much nausea.

References

Every citation below links to the original peer-reviewed record on PubMed or via DOI. Nothing here is a substitute for medical advice.

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Kristensen SL, Rørth R, Jhund PS, et al. · The lancet. Diabetes & endocrinology · 2019 · Meta-analysis DOI PubMed 31422062
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes Rosenstock J, Hsia S, Nevarez Ruiz L, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOI PubMed 40544435
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment Wharton S, Aronne LJ, Stefanski A, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOI PubMed 40960239
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity Wharton S, Blevins T, Connery L, et al. · The New England journal of medicine · 2023 · Randomised controlled trial DOI PubMed 37351564
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Rosenstock J, Wysham C, Frías JP, et al. · Lancet (London, England) · 2021 · Randomised controlled trial DOI PubMed 34186022
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes Frías JP, Davies MJ, Rosenstock J, et al. · The New England journal of medicine · 2021 · Randomised controlled trial DOI PubMed 34170647
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Gerstein HC, Colhoun HM, Dagenais GR, et al. · Lancet (London, England) · 2019 · Randomised controlled trial DOI PubMed 31189511
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept Coskun T, Sloop KW, Loghin C, et al. · Molecular metabolism · 2018 · Randomised controlled trial DOI PubMed 30473097 Full text
Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies Thomsen RW, Mailhac A, Løhde JB, et al. · Diabetes, obesity & metabolism · 2025 · Review DOI PubMed 40196933 Full text